FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. [electronic resource]
Producer: 20200427Description: 502-513 p. digitalISSN:- 1539-2864
- Adult
- Aged
- Antineoplastic Agents -- adverse effects
- Enzyme Inhibitors -- adverse effects
- Female
- Humans
- Hydroxychloroquine -- adverse effects
- Imidazoles -- adverse effects
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- Macula Lutea -- pathology
- Male
- Melanoma -- drug therapy
- Middle Aged
- Oximes -- adverse effects
- Photoreceptor Cells -- pathology
- Protein Kinase Inhibitors -- adverse effects
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Pyridones -- adverse effects
- Pyrimidinones -- adverse effects
- Retinal Diseases -- chemically induced
- Retinal Pigment Epithelium -- pathology
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.